Jump to: navigation, search
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
  •  ?
Routes of
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life26-200 hours
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass368.8
3D model (JSmol)

WikiDoc Resources for Ketazolam


Most recent articles on Ketazolam

Most cited articles on Ketazolam

Review articles on Ketazolam

Articles on Ketazolam in N Eng J Med, Lancet, BMJ


Powerpoint slides on Ketazolam

Images of Ketazolam

Photos of Ketazolam

Podcasts & MP3s on Ketazolam

Videos on Ketazolam

Evidence Based Medicine

Cochrane Collaboration on Ketazolam

Bandolier on Ketazolam

TRIP on Ketazolam

Clinical Trials

Ongoing Trials on Ketazolam at Clinical

Trial results on Ketazolam

Clinical Trials on Ketazolam at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ketazolam

NICE Guidance on Ketazolam


FDA on Ketazolam

CDC on Ketazolam


Books on Ketazolam


Ketazolam in the news

Be alerted to news on Ketazolam

News trends on Ketazolam


Blogs on Ketazolam


Definitions of Ketazolam

Patient Resources / Community

Patient resources on Ketazolam

Discussion groups on Ketazolam

Patient Handouts on Ketazolam

Directions to Hospitals Treating Ketazolam

Risk calculators and risk factors for Ketazolam

Healthcare Provider Resources

Symptoms of Ketazolam

Causes & Risk Factors for Ketazolam

Diagnostic studies for Ketazolam

Treatment of Ketazolam

Continuing Medical Education (CME)

CME Programs on Ketazolam


Ketazolam en Espanol

Ketazolam en Francais


Ketazolam in the Marketplace

Patents on Ketazolam

Experimental / Informatics

List of terms related to Ketazolam

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Ketazolam (marketed under the brand names Anseren, Ansieten, Ansietil, Marcen, Sedatival, Sedotime, Solatran and Unakalm) is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties.

Therapeutic uses

It is used for the treatment of anxiety and has similar effectiveness compared to diazepam. Ketazolam also appears to produce a reduced level of side effects such as sedation compared with diazepam and the side effects when they occur tend to be milder.[2][3][4][5] Ketazolam is also an effective antispasmodic drug and is used for the treatment of spasticity.[6][7][8]


Ketazolam is not approved for sale in Australia, United Kingdom or the United States.[9] In South Africa, GlaxoSmithKline markets ketazolam under its Solatran brand name.[10] In Canada, ketazolam is listed in schedule IV of the Controlled Drugs and Substances Act, along with other benzodiazepines.[11]

Tolerance and physical dependence

Chronic use of ketazolam as with other benzodiazepines can lead to physical dependence and the appearance of the benzodiazepine withdrawal syndrome upon cessation of use or decrease in dose. Tolerance to ketazolam's therapeutic effects occurs over a period of 15 days.[12]

Contraindications and special caution

Benzodiazepines require special precaution if used in the elderly, during pregnancy, in children, alcohol or drug-dependent individuals and individuals with comorbid psychiatric disorders.[13]


Ketazolam breaks down in the blood to diazepam which breaks down to demoxepam which breaks down to desmethyldiazepam.[14]


The U.S. Food and Drug Administration warns that in Spain, ketazolam marketed as Marcen may sometimes be mistakenly confused with Narcan.[15]

Legal status

Ketazolam is a List 3 drug under the Betäubungsmittelgesetz, like almost all benzodiazepines in Germany. Ketazolam is a List II drugs of the Opium Law in the Netherlands. Ketazolam is a Schedule IV drug under the Controlled Substances Act in the US.[16]


  1. Vega D; Fernández D; Echeverría G (July 2001). "Ketazolam". Acta Crystallogr C. 57 (Pt 7): 848–50. doi:10.1107/S0108270101006175. PMID 11443263.
  2. Anhalt HS; Young R; Roginsky M (November 1980). "Double-blind comparison of ketazolam, diazepam and placebo in once-a-day vs t.i.d. dosing". The Journal of clinical psychiatry. 41 (11): 386–92. PMID 6108319.
  3. Kim KK; Sirman A; Trainor FS; Lee BY (1980). "Anxiolytic efficacy and safety of ketazolam compared with diazepam and placebo". Clin Ther. 3 (1): 9–14. PMID 6105920.
  4. Fabre LF Jr; Harris RT (1976). "Double-blind placebo-controlled efficacy study of ketazolam (U-28,774)". J Int Med Res. 4 (1): 50–4. PMID 16791.
  5. Rickels K; Csanalosi I; Greisman P; Mirman MJ; Morris RJ; Weise CC; Weiss G (October 1980). "Ketazolam and diazepam in anxiety: a controlled study". J Clin Pharmacol. 20 (10): 581–9. doi:10.1002/j.1552-4604.1980.tb01673.x. PMID 6108335.
  6. Basmajian JV; Shankardass K; Russell D (August 1986). "Ketazolam once daily for spasticity: double-blind cross-over study". Arch Phys Med Rehabil. 67 (8): 556–7. PMID 2874780.
  7. Katz RT (June 1988). "Management of spasticity". Am J Phys Med Rehabil. 67 (3): 108–16. doi:10.1097/00002060-198806000-00004. PMID 3288246.
  8. Basmajian JV; Shankardass K; Russell D; Yucel V (November 1984). "Ketazolam treatment for spasticity: double-blind study of a new drug". Arch Phys Med Rehabil. 65 (11): 698–701. PMID 6149738.
  9. "Benzodiazepine Names". The Tranquilliser Recovery and Awareness Place. Retrieved 26 August 2008.
  10. "SOLATRAN 15 (capsules) - SOLATRAN 30 (capsules)". South African Electronic Package Inserts. 12 November 1985. Retrieved 26 August 2008.
  12. Higgitt A; Fonagy P; Lader M (1988). "The natural history of tolerance to the benzodiazepines". Psychol Med Monogr Suppl. 13: 1–55. doi:10.1017/S0264180100000412. PMID 2908516.
  13. Authier, N.; Balayssac, D.; Sautereau, M.; Zangarelli, A.; Courty, P.; Somogyi, AA.; Vennat, B.; Llorca, PM.; Eschalier, A. (Nov 2009). "Benzodiazepine dependence: focus on withdrawal syndrome". Ann Pharm Fr. 67 (6): 408–13. doi:10.1016/j.pharma.2009.07.001. PMID 19900604.
  14. Joyce JR, Bal TS, Ardrey RE, Stevens HM, Moffat AC (June 1984). "The decomposition of benzodiazepines during analysis by capillary gas chromatography/mass spectrometry". Biomed Mass Spectrom. 11 (6): 284–9. doi:10.1002/bms.1200110607. PMID 6743768.
  15. Food and Drug Administration (January 2006). "FDA Public Health Advisory - Consumers Filling U.S. Prescriptions Abroad May Get the Wrong Active Ingredient Because of Confusing Drug Names". FDA (USA). Archived from the original on 12 August 2006. Retrieved 26 August 2006.
  16. Drug Enforcement Administration (USA). "Drug Scheduling". United States Government. Retrieved 26 August 2008.